STAT3 and pulmonary arterial hypertension: Renard et al. described cases of PAH development or progression during sofosbuvir treatment, which was attributed to a rapid decrease in vasodilatory mediators following HCV eradication and secondary activation of the STAT3 axis, potentially unmasking latent or previously stable PAH [224].